STAT Plus Karyopharm hides higher death rate tied to blood cancer drug dimming approval hopes

STAT Plus: Karyopharm hides higher death rate tied to blood cancer drug, dimming approval hopes

An experimental cancer drug made by Karyopharm Therapeutics hastened the death of patients with an advanced form of leukemia, but the company never publicly disclosed the negative outcome.

More From BioPortfolio on "STAT Plus: Karyopharm hides higher death rate tied to blood cancer drug, dimming approval hopes"